Phase I/II study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine in patients with advanced pancreatic cancer Phase I part: - To determine the maximum tolerated dose (MTD) and recommended dose (RD) of human L19IL2 in combination with gemcitabine in advanced solid tumour patients for whom gemcitabine is a sui...

• Country None
• organs None
• Specialty None